Login to Your Account

Onyx Skyrockets On Phase III Nexavar Data In Liver Cancer

By Jennifer Boggs

Tuesday, February 13, 2007
Shares of Onyx Pharmaceuticals Inc. soared more than 95 percent on news that its kidney cancer drug, Nexavar, yielded positive survival data in a Phase III trial in liver cancer patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription